Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
Contact your MP or a Member of the House of Lords about an issue that matters to you
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House observes that between 7,000 and 8,000 people are diagnosed with kidney cancer in the UK each year, and that around 40 per cent. of patients have advanced cancer at the time of diagnosis; notes that everolimus is the only licensed treatment for patients with advanced and/or metastatic renal cell carcinoma who have failed on first-line treatment; notes with concern that the National Institute for Health and Clinical Excellence (NICE) has not recommended funding for everolimus; is concerned by the number of clinically effective cancer drugs which are turned down by NICE despite additional guidance on end-of-life medicines issued by NICE to the appraisal committees; and calls on NICE to reconsider its recommendations so that patients may be able to access this drug on the NHS.
Total number of signatures: 43
Showing 43 out of 43